Products
Statiglin
Pharmacotherapeutic group
Oral hypoglycemic agent, second generation sulfonylurea derivativeInternational name
GlibenclamideDosage form
TabletsProduct information
Download Statiglin.pdf (RU)
Go to the State Register of Medicinal Products site ➞
Oral hypoglycemic drug, second generation sulfonylurea derivative. Glibenclamide stimulates insulin secretion by pancreatic beta cells and increases insulin release. It acts mainly in the second phase of insulin secretion. It also increases sensitivity of peripheral tissues to insulin and its binding to target cells. It has a hypoglycemic effect and reduces blood thrombogenicity.